{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:36:27Z","timestamp":1785375387678,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejps.2020.105498","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T21:19:10Z","timestamp":1595971150000},"page":"105498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-4121","authenticated-orcid":false,"given":"Eleni","family":"Karatza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-0712","authenticated-orcid":false,"given":"Vangelis","family":"Karalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105498_bib0001","unstructured":"Aprovel\u00ae Summary of product Characteristics (2019), Sanofi -Aventis group, Paris - France."},{"key":"10.1016\/j.ejps.2020.105498_bib0002","first-page":"19","article-title":"The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review","volume":"19","author":"Borghi","year":"2012"},{"issue":"2","key":"10.1016\/j.ejps.2020.105498_bib0003","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jchromb.2003.11.009","article-title":"Simultaneous determination of the acid\/base antihypertensive drugs celiprolol, bisoprolol and irbesartan in human plasma by liquid chromatography","volume":"801","author":"Caudron","year":"2004","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.ejps.2020.105498_bib0004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput. Methods Programs Biomed."},{"issue":"1","key":"10.1016\/j.ejps.2020.105498_bib0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-9556(24)15006-4","article-title":"Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques","volume":"28","author":"Davi","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2020.105498_bib0006","series-title":"Surveys and Tutorials in the Applied Mathematical Sciences","first-page":"1","article-title":"Applied delay differential equations","author":"Erneux","year":"2009"},{"key":"10.1016\/j.ejps.2020.105498_bib0007","unstructured":"European Medicines Agency (EMA), 2004. Aprovel\/Karvea\u00ae INN-Irbesartan, public assessment repost, scientific discussion, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/karvea-epar-scientific-discussion_en.pdf (last accessed on March 2020)."},{"key":"10.1016\/j.ejps.2020.105498_bib0008","unstructured":"European Medicines Agency (EMA), 2010. Committee for medicinal products for human use (CHMP), guideline on the investigation of bioequivalence, Doc. Ref.: CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr **, London, UK."},{"issue":"6","key":"10.1016\/j.ejps.2020.105498_bib0009","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0149-2918(01)80075-8","article-title":"A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe","volume":"23","author":"Ezzet","year":"2001","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.ejps.2020.105498_bib0010","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1208\/s12248-012-9389-7","article-title":"Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs","volume":"14","author":"Gao","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2020.105498_bib0011","first-page":"575","article-title":"Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan","volume":"9","author":"Gialama","year":"2013","journal-title":"Vasc Health Risk Manag."},{"issue":"Jun","key":"10.1016\/j.ejps.2020.105498_bib0012","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2018.03.002","article-title":"Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water","volume":"127","author":"Grimm","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"10","key":"10.1016\/j.ejps.2020.105498_bib0013","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/10837450.2018.1536996","article-title":"Physiological parameters of the gastrointestinal fluid impact the dissolution behavior of the BCS class IIa drug valsartan","volume":"23","author":"Hamed","year":"2018","journal-title":"Pharm. Dev. Technol."},{"issue":"4","key":"10.1016\/j.ejps.2020.105498_bib0014","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/bdd.1935","article-title":"Modeling of the pharmacokinetic\/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects","volume":"36","author":"Hedaya","year":"2015","journal-title":"Biopharm. Drug Dispos."},{"issue":"12","key":"10.1016\/j.ejps.2020.105498_bib0015","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1021\/acs.molpharmaceut.7b00396","article-title":"In silico modeling approach for the evaluation of gastrointestinal dissolution, supersaturation, and precipitation of posaconazole","volume":"14","author":"Hens","year":"2017","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.ejps.2020.105498_bib0016","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ejpb.2008.02.022","article-title":"Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans","volume":"70","author":"Higaki","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.ejps.2020.105498_bib0017","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF01061464","article-title":"Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil","volume":"20","author":"Holford","year":"1992","journal-title":"J. Pharmacokinet Biopharm."},{"issue":"4","key":"10.1016\/j.ejps.2020.105498_bib0018","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF03190465","article-title":"PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions","volume":"31","author":"Huang","year":"2006","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ejps.2020.105498_bib0019","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/FTD.0b013e31819c077c","article-title":"Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients","volume":"31","author":"Hulin","year":"2009","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.ejps.2020.105498_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bcpt.13321","article-title":"Modelling gastric emptying: a pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174","volume":"126","author":"Karatza","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.ejps.2020.105498_bib0021","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1208\/s12248-015-9764-2","article-title":"Population pharmacokinetic modeling of the enterohepatic recirculation of fimasartan in rats, dogs, and humans","volume":"17","author":"Kim","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2020.105498_bib0022","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10928-014-9368-y","article-title":"Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations","volume":"41","author":"Koch","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"2","key":"10.1016\/j.ejps.2020.105498_bib0023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejps.2006.10.011","article-title":"Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates","volume":"30","author":"Kortej\u00e4rvi","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105498_bib0024","unstructured":"Kuate R, Lavielle M, Blaudez E, Chatel K, Marquet K, Si Abdallah JF., 2014. A delay differential equation solver for MONOLIX & MLXPLORE. Research report RR-8489, INRIA.19."},{"issue":"4","key":"10.1016\/j.ejps.2020.105498_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF03190880","article-title":"Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data","volume":"33","author":"Kumar","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.ejps.2020.105498_bib0026","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/bdd.2510150902","article-title":"Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH","volume":"15","author":"Langguth","year":"1994","journal-title":"Biopharm. Drug Dispos."},{"issue":"3","key":"10.1016\/j.ejps.2020.105498_bib0027","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF02354285","article-title":"Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs","volume":"23","author":"Lipka","year":"1995","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"2","key":"10.1016\/j.ejps.2020.105498_bib0028","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/03602532.2016.1157600","article-title":"Role of enterohepatic recirculation in drug disposition: cooperation and complications","volume":"48","author":"Malik","year":"2016","journal-title":"Drug Metab. Rev."},{"issue":"1","key":"10.1016\/j.ejps.2020.105498_bib0029","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00005344-200207000-00014","article-title":"Pharmacokinetics of irbesartan are not altered in special populations","volume":"40","author":"Marino","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2020.105498_bib0030","first-page":"87","article-title":"& Model evaluation group of the international society of pharmacometrics (ISoP) best practice committee","volume":"6","author":"Nguyen","year":"2017","journal-title":"Model Eval. Contin. Data Pharmacomet. Models: Metrics Graphics. CPT: Pharmacomet. Syst. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2020.105498_bib0031","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF01061761","article-title":"The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon","volume":"15","author":"Oberle","year":"1987","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"5","key":"10.1016\/j.ejps.2020.105498_bib0032","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0016-5085(90)91150-5","article-title":"The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids","volume":"99","author":"Oberle","year":"1990","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ejps.2020.105498_bib0033","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1208\/s12248-014-9693-5","article-title":"Empirical and semi- mechanistic modelling of double-peaked pharmacokinetic profile phenomenon due to gastric emptying","volume":"17","author":"Ogungbenro","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2020.105498_bib0034","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejpb.2018.05.033","article-title":"Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach","volume":"129","author":"Paix\u00e3o","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7","key":"10.1016\/j.ejps.2020.105498_bib0035","first-page":"S15","article-title":"Human pharmacokinetic\/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist","volume":"15","author":"Ruilope","year":"1997","journal-title":"J. Hypertens. Suppl."},{"issue":"4","key":"10.1016\/j.ejps.2020.105498_bib0036","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejps.2013.05.019","article-title":"In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim","volume":"49","author":"Sj\u00f6gren","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejps.2020.105498_bib0037","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/00498254.2018.1463117","article-title":"On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe","volume":"49","author":"Soulele","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2020.105498_bib0038","series-title":"Biopharmaceutics Modeling and Simulations: Theory, Practice, Methods, and Applications","first-page":"171","author":"Sugano","year":"2012"},{"issue":"1","key":"10.1016\/j.ejps.2020.105498_bib0039","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0939-6411(01)00207-7","article-title":"Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility","volume":"53","author":"Takamatsu","year":"2002","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.ejps.2020.105498_bib0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1021\/acs.molpharmaceut.5b00774","article-title":"Gastrointestinal motility variation and implications for plasma level variation: oral drug products","volume":"13","author":"Talattof","year":"2016","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.ejps.2020.105498_bib0041","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/bdd.1800","article-title":"In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen","volume":"33","author":"Tsume","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2020.105498_bib0042","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejps.2014.01.009","article-title":"The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC","volume":"57","author":"Tsume","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.ejps.2020.105498_bib0043","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/j.1552-4604.1998.tb04809.x","article-title":"Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers","volume":"38","author":"Vachharajani","year":"1998","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejps.2020.105498_bib0044","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/j.1552-4604.1998.tb04449.x","article-title":"Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers","volume":"38","author":"Vachharajani","year":"1998","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2020.105498_bib0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejpb.2009.07.007","article-title":"Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract","volume":"74","author":"Weitschies","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:55:54Z","timestamp":1760529354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720302876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":45,"alternative-id":["S0928098720302876"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105498","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105498"}}